Table 5.
Differences between cirrhotic and non-cirrhotic hepatocellular carcinoma patients
| Parameter | Cirrhotic HCC | Non-cirrhotic HCC | p value |
|---|---|---|---|
| Age (years) | 61.78 ± 9.51 | 65.57 ± 11.52 | 0.002% |
| Size (cm) | 6.22 ± 3.78 | 11.32 ± 4.67 | < 0.005% |
| BCLC–O/ A/ B/ C/ D | 6/ 29/ 50/ 121/ 42 | 0/ 6/ 36/ 45/ 4 | < 0.005* |
| ALBI–1/ 2/ 3 | 20/ 139/ 89 | 30/ 53/ 8 | < 0.005* |
| Okuda–I/ II/ III | 40/ 152/ 56 | 20/ 61/ 10 | 0.036* |
| CTP–A/ B/ C | 77/ 129/ 42 | 62/ 25/ 4 | < 0.005* |
| MELD | 13.22 ± 5.22 | 10.23 ± 4.04 | < 0.005* |
| AFP (ng/mL) | 13877 ± 39190 | 17401 ± 35836 | ns % |
| NLR | 4.25 ± 3.38 | 5.02 ± 5.09 | ns % |
| PLR | 132.11 ± 94.92 | 230.72 ± 168.55 | < 0.001% |
| Thrombosis–yes/ no | 121/ 125 | 61/ 30 | 0.007* |
Variables expressed as % of total patients according to stages of BCLC, ALBI, Okuda, and CTP. AFP levels (in ng/mL), NLR (neutrophil-lymphocyte ratio), and PLR (platelet lymphocyte ratio) were expressed as mean ± SD
*Chi-square test, % independent student t-test; p<0.05 is significant; ns=not significant
BCLC Barcelona Clinic Liver Cancer staging, ALBI Albumin-Bilirubin grading, CTP Child-Turcotte-Pugh score, MELD model for end-stage liver disease score, AFP alpha- fetoprotein, NLR neutrophil-lymphocyte ratio, PLR platelet lymphocyte ratio